Emcure Pharmaceuticals (India) Today
| EMCURE Stock | 1,387 13.80 1.01% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Emcure Pharmaceuticals is trading at 1386.70 as of the 22nd of December 2024, a 1.01 percent increase since the beginning of the trading day. The stock's open price was 1372.9. Emcure Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 25th of June 2024 and ending today, the 22nd of December 2024. Click here to learn more.
Category Healthcare |
Emcure Pharmaceuticals is entity of India. It is traded as Stock on NSE exchange. More on Emcure Pharmaceuticals
Moving together with Emcure Stock
Moving against Emcure Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Emcure Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Emcure Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Emcure Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| MD CEO | Satish Mehta |
| Business Concentration | Drug Manufacturers - Specialty & Generic, Healthcare, Drug Manufacturers - Specialty & Generic, Healthcare (View all Sectors) |
Emcure Pharmaceuticals (EMCURE) is traded on National Stock Exchange of India in India and employs 10 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 270.98 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Emcure Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Emcure Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Emcure Pharmaceuticals operates under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry.
Check Emcure Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Emcure Pharmaceuticals is USD270.98 Billion. Emcure Pharmaceuticals shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 86.77 percent of Emcure Pharmaceuticals outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Check Emcure Ownership Details
Emcure Pharmaceuticals Risk Profiles
Although Emcure Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Emcure Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.64 | |||
| Standard Deviation | 2.33 | |||
| Variance | 5.45 | |||
| Risk Adjusted Performance | 0.0027 |
Emcure Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Emcure Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Emcure Pharmaceuticals Corporate Directors
| Naveen Soni | Director Relations | Profile | |
| Mukund Gurjar | Chief Director | Profile | |
| Namita Thapar | Executive Director | Profile | |
| Sunil Mehta | Executive Director | Profile |
Other Information on Investing in Emcure Stock
Emcure Pharmaceuticals financial ratios help investors to determine whether Emcure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Emcure with respect to the benefits of owning Emcure Pharmaceuticals security.